Early results from the randomized Recovery trial of drugs to treat COVID-19 patients could be available in early July, as reported in the National Post.
The first data from the study, which is testing certain existing drugs, is likely to come from low-dose dexamethasone, said Martin Landray, one of the scientists leading the UK-based study.
"There is unlikely to be a single big win" from the trials, which is why the project is testing several existing medicines to see if they might be able to be repurposed to help treat COVID-19, Landray said.
Other drugs being tested are hydroxychloroquine, lopinavir-ritonavir, azithromycin and convalescent plasma.
The trial has so far enrolled 11,000 patients ranging from one to 109 years of ages at 175 UK hospitals since it was set up in March, according to Landray.
To read more NewsPoints articles, click here.